Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sirnaomics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The docket involves 5 distinct examiners across 4 art units, requiring coordination across multiple examination assignments.
HUDSON, AMY ROSE is the busiest examiner, with 1 pending matter. The equal examiner distribution means that docket management should emphasize tailored responses for each matter rather than relying on a dominant examiner relationship.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 5 (83%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 63.9% | +18.1% |
| GIBBS, TERRA C | 1 | 63.7% | +10.4% |
| ARIETI, RUTH SOPHIA | 1 | 46.2% | +71.4% |
| COHEN, MICHAEL P | 1 | 58.9% | +27.3% |
| ZAHORIK, AMANDA MARY | 1 | 58.3% | +49.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 6d |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 9d |
| 18355280 | METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS | HUDSON, AMY ROSE | — |
| 17935014 | NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS | COHEN, MICHAEL P | — |
| 17215964 | Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets | ZAHORIK, AMANDA MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 6d |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 9d |
| 18355280 | METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS | HUDSON, AMY ROSE | — |
| 18170971 | PRODUCTS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | — |
| 17935014 | NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS | COHEN, MICHAEL P | — |
| 17215964 | Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets | ZAHORIK, AMANDA MARY | — |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1635 | 2 |
| 1637 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18355280 | METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Jul 19, 2023 |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103Other | Non-Final OA | 9d | Pending | Mar 24, 2023 |
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 1635 | §103§112Other | Final Rejection | 6d | Pending | Mar 07, 2023 |
| 18170971 | PRODUCTS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | 1635 | §103§112DP | Non-Final OA | — | Pending | Feb 17, 2023 |
| 17935014 | NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS | COHEN, MICHAEL P | 1612 | §103§112 | Final Rejection | — | Pending | Sep 23, 2022 |
| 17215964 | Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets | ZAHORIK, AMANDA MARY | 1636 | §102§103§112Other | Non-Final OA | — | Pending | Mar 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSirnaomics Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Amy Rose Hudson has the most, with 1 of Sirnaomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
